Wednesday, March 22, 2017

Introducing the PLUS Study


The George Institute of Global Health, Sydney, is our newest client and the coordinating centre for the PLUS Study.  PLUS kicked off in February and will begin taking enrolments in July.

Another fluid resuscitation study for us, the PLUS Study is a multi-centre, blinded, RCT.

PLUS tests the hypothesis that:
"in a heterogeneous population of critically ill adults, random assignment to Plasma-Lyte 148® for intravascular volume resuscitation and crystalloid fluid therapy in the Intensive Care Unit (ICU) results in different 90-day all-cause mortality when compared with random assignment to 0.9% sodium chloride (saline) for the same treatment."
Of note:
  • with 8,800 patients this will be our biggest study
  • the study uses our inventory module to track all treatment from shipment to disposal
  • the study will initially run in Australia and New Zealand with other countries coming on board later
Next Tuesday I am off to Sydney to meet with the project manager and chief investigator for a sanity check which will ensure the project is going in the right direction. In the meeting we will take a strategic look at the project, discuss the more complex issues in the project and and check-in on our assumptions. I always enjoy these get togethers and once we are underway I find it important to make sure we are all walking along the same path with the project.

It’s always good to see people face to face and I regularly pop across the Tasman to meet with the project admins or join in a team meeting, even if just for an hour, although sometimes I can spend six hours with a project manager, nutting out detail. Mostly I can get across the ditch, and back, in a day but I am always happy to stay longer and use the opportunity to catch up with some of our other trials that are underway.

Thursday, January 19, 2017

Working smarter with online software

Spiral is a distributed company ...we are the ones that bring you Spinnaker! Distributed means our team work from homes and offices across New Zealand. Its a great way to work, it enables us to be focused, work smartly and avoid earthquake issues!

We rely heavily on great communication and technology and I thought you might be interested in some of the software tools we use:

  • Skype. For video and voice calls with customers and internally. We use the screen sharing function on Skype a lot
  • Slack. For team chat and water-cooler type conversations.  Some of our other apps are  integrated with Slack so that we get messages when stuff is happening on other channels
  • Bugherd. For reporting bugs and issues with Spinnaker. Some customers will recognise this one because you are using it
  • dapulse. Gives us a way to visualise all our projects and deliver working, robust software in a timely manner
  • Inspectlet. Records peoples behaviour using Spinnaker which we translate into improvements to our software that make your experience of it better or quicker
  • Highrise. CRM that helps me stay organised

Im currently evaluating Zendesk but thats a story for another day.

My desk - a distributed office environment can look like this. 

Tuesday, December 20, 2016

Thanks for being on-board

Thanks for being on board and for your support this year. We have more projects open and trials taking enrolments than any other year and we couldn’t do that without your support.  What a year!

Supporting your research is why we come to work each day. Here are some of the highlights in our year:
  • over 1,480 patients were randomised using Spinnaker
  • Deb Gilbertson joined the team at Spiral in the role of development support
  • we entirely rewrote the user-permissions module for Spinnaker ready for more complex studies
  • we started work on ANZ’s first response adaptive platform trial (REMAP-CAP)
Like you we have been working hard through the year. To recharge and get ready for 2017 we will close on the 22nd of December and reopen on the 16th of January 2017.   

OUR SUPPORT FOR YOU NEVER STOPS. While you are playing cricket on the beach or eating too much ham, our infrastructure team will be monitoring Spinnaker, making sure everything is running smoothly and that your trials can be accessed when you need them. 

Merry Xmas from everyone @ Spiral


Thursday, November 10, 2016

Self-learning trial to use Spinnaker software


I am excited to announce Spiral have joined the team working on the first response adaptive platform trial to be based in Australia and New Zealand(REMAP-CAP).  The self-learning design for this clinical trial is an exciting new methodology that significantly reduces the time and number of patients needed to test treatments while increasing safety for trial participants.

For this project our Spinnaker software will be used in Australian and New Zealand ICUs to test questions related to community acquired pneumonia.  Spinnakers adaptability is a key factor in this self-learning/adaptive trial.

Trial funding
The trial is funded by the Health Research Council of New Zealand(HRC) and the National Health and Medical Research Council of Australia(NHMRC).

General Characteristics of a Platform Trial
  • A novel and innovative trial design that is highly adaptive and utilises frequent Bayesian interim analyses to answer as many questions as possible from the available sample
  • Simultaneously evaluates the effectiveness of multiple alternative treatment options in a heterogeneous population including identifying any interactions between treatments
  • Evaluates treatment effects in sub-groups
  • Allows modification of key trial parameters in response to accumulated information and predefined rules
  • Preferentially randomises participants to treatments that are likely to be more effective, leading to better outcomes for patients within the trial. 



Self-learning trial to use Spinnaker software


I am excited to announce Spiral have joined the team working on the first response adaptive platform trial to be based in Australia and New Zealand(REMAP-CAP).  The self-learning design for this clinical trial is an exciting new methodology that significantly reduces the time and number of patients needed to test treatments while increasing safety for trial participants.

For this project our Spinnaker software will be used in Australian and New Zealand ICUs to test questions related to community acquired pneumonia.  Looks like Spiral really does have the most adaptable clinical trial software in ANZ!

Trial funding
The trial is funded by the Health Research Council of New Zealand(HRC) and the National Health and Medical Research Council of Australia(NHMRC).

General Characteristics of a Platform Trial
  • A novel and innovative trial design that is highly adaptive and utilises frequent Bayesian interim analyses to answer as many questions as possible from the available sample
  • Simultaneously evaluates the effectiveness of multiple alternative treatment options in a heterogeneous population including identifying any interactions between treatments
  • Evaluates treatment effects in sub-groups
  • Allows modification of key trial parameters in response to accumulated information and predefined rules
  • Preferentially randomises participants to treatments that are likely to be more effective, leading to better outcomes for patients within the trial. 


Self-learning trial to use Spinnaker software


I am excited to announce Spiral have joined the team working on the first response adaptive platform trial to be based in Australia and New Zealand(REMAP-CAP).  The self-learning design for this clinical trial is an exciting new methodology that significantly reduces the time and number of patients needed to test treatments while increasing safety for trial participants.

For this project our Spinnaker software will be used in Australian and New Zealand ICUs to test questions related to community acquired pneumonia.  Looks like Spiral really does have the most adaptable clinical trial software in ANZ! 
Trial funding
The trial is funded by the Health Research Council of New Zealand(HRC) and the National Health and Medical Research Council of Australia(NHMRC).

General Characteristics of a Platform Trial
  • A novel and innovative trial design that is highly adaptive and utilises frequent Bayesian interim analyses to answer as many questions as possible from the available sample
  • Simultaneously evaluates the effectiveness of multiple alternative treatment options in a heterogeneous population including identifying any interactions between treatments
  • Evaluates treatment effects in sub-groups
  • Allows modification of key trial parameters in response to accumulated information and predefined rules
  • Preferentially randomises participants to treatments that are likely to be more effective, leading to better outcomes for patients within the trial.